Treatment of infections due to methicillin-resistant Staphylococcus aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents treatment challenges due to its resistance to beta-lactam antibiotics.
• In vitro studies reveal inconsistent susceptibility of MRSA strains to cephalosporins, with some strains showing resistance despite initial susceptibility indications.

Purpose of the Study:

• To evaluate the in vitro susceptibility of MRSA strains to various antibiotics.
• To determine the optimal therapeutic strategies for MRSA infections.

Main Methods:

• In vitro susceptibility testing using standard disk diffusion and quantitative dilution methods.
• Assessment of antibiotic combinations, including vancomycin, rifampin, and aminoglycosides.

Main Results:

• MRSA strains exhibit heterogeneous in vitro responses to cephalosporins.
• Vancomycin demonstrates consistent in vitro susceptibility against MRSA.
• In vitro antagonism observed between vancomycin and rifampin.

Conclusions:

• Vancomycin is the recommended first-line treatment for MRSA infections.
• Combination therapy with aminoglycosides or rifampin may be considered for refractory cases.
• Monitoring serum bactericidal titers and conducting in vitro time-kill studies are crucial for guiding treatment decisions.